

ESSO ADVANCED COURSE ON THE TREATMENT OF PERITONEAL SURFACE MALIGNANCY

In partnership with Universiteit Hasselt, Biomed Research
Institute

Program

Thursday 12 October

- | | |
|-------------|--|
| 11.30-12.30 | Registration and Lunch |
| 12.30-12.45 | Welcome, Aims and Objectives of the Advanced Course
<i>K. Van der Speeten, S. González-Moreno</i> |
| 12.45-13.15 | Keynote address:

Peritoneal Surface Malignancy (PSM) Treatment in 2017:
Historical Perspective
<i>P. Sugarbaker</i> |

Session 1 : Scientific Background of PSM

- | | |
|--------------|---|
| 13.15-13.40 | Pathophysiology of PSM

<i>Y. Yonemura</i> |
| 13.40 -14.00 | PSM: Risk factors and Natural History
<i>F. Quenet</i> |

Session 2 : Cytoreductive Surgery

- | | |
|-------------|---|
| 14.00-15.15 | Surgical Technique: tips and tricks (video session)

<ol style="list-style-type: none">1. Upper Abdomen CRS
<i>P. Piso</i>2. Pelvic CRS
<i>F. Mohamed</i>3. Central abdomen
<i>M. Deraco</i>4. Technology & Technique of HIPEC, EPIC,NIPS
<i>P. Cashin</i> |
|-------------|---|

15.15-15.30 *Coffee break*

Session 3 : Intraperitoneal Chemotherapy

- 15.30-15.45 Rationale for IP Chemotherapy: Pharmacokinetics
F. Mohamed
- 15.45-16.00 Rationale for IP Chemotherapy: Pharmacodynamics
W. Ceelen
- 16.00-16.30 Keynote address:
Chemotherapeutic agents for IP Chemotherapy
M. Pocard

Session 4 : Setting up a PSM Center

- 16.45-17.00 Setting up a PSM Center: challenges and opportunities
T. Bachleitner-Hofman
- 17.00-17.15 Learning curve and networks
A. Bhatt
- 17.15-17.30 Role of the radiologist in PSM
E. Dresen
- 17.30-17.45 Role of the anesthesiologist in PSM
UZ Gent speaker
- 17.45-18.00 Complications: how to avoid and to treat
B. Rau
- 18.00-19.30 Welcome Reception and Dinner

Friday 13 October

Disease Specific Challenges

- 8.15-8.30 Live Surgery from the OR: introduction of the case
K. Van der Speeten, P. Sugarbaker

Session 1: Appendiceal PSM

- 8.30-8.50 Pathology of Appendiceal PSM and Neoplasia
N. Carr

8.50 -9.10 CRS and HIPEC for appendiceal PSM
S. González-Moreno

9.10-9.30 Interactive Case Presentations and MDT
F. Quenet

9.30-9.45 Update from the OR

9.45-10.00 Coffee break

Session 2: Colorectal PSM

10.00-10.20 CRS and HIPEC for Colorectal PSM
V. Verwaal

10.20-10.40 Keynote address:
Role of Systemic Chemotherapy in Colorectal PSM
E. Van Cutsem

10.40-11.00 Interactive Case Presentations and MDT
M. Pocard

11.00-11.15 Update from the OR

Session 3: Gastric PSM

11.15-11.40 Keynote address:
Role of IP (HIPEC, EPIC, NIPS) chemotherapy in gastric PSM
Y. Yonemura

11.40-12.00 Interactive Case Presentations and MDT
O. Glehen

12.00-12.10 Update from the OR

12.10-13.10 Lunch

Session 4: Ovarian PSM

13.10-13.35 Keynote address:
Evolving Role of IP Chemotherapy in Ovarian PSM
W. Van Driel

13.35-13.55 Interactive Case Presentations and MDT
M. Deraco

13.55-14.05 Update from the OR

Session 5: Patient Selection and Follow-Up

- | | |
|--------------|--|
| 14.05-14.25 | Patient Selection: How I do it.
S. O'Dwyer |
| 14.25-14.45 | Patient follow-up: How and for how long?
P.Piso |
| 14.45-15.05 | Postoperative Care, Nutrition and Enhanced Recovery
B.Rau |
| 15.05-15.15 | Update from the OR |
| 15.15 -15.30 | <i>Coffee break</i> |

Session 6: Pushing the Boundaries

- | | |
|-------------|--|
| 15.30-15.50 | Unusual Indications for CRS and IP Chemotherapy
<i>V. Verwaal</i> |
| 15.50-16.10 | PIPAC: Rationale, Indications and Results
<i>M. Reymond</i> |
| 16.10-16.30 | CRS and HIPEC as a Palliative Strategy
<i>S. O'Dwyer</i> |
| 16.30-17.00 | Keynote address:
'Prophylactic' HIPEC: moving IP Chemotherapy upfront in the
Timeline of PSM
<i>O. Glehen</i> |
| 17.00-17.30 | Wrap-up from the OR |

Saturday 14 October

Session 1: Mesothelioma

- | | |
|-----------|--|
| 8.30-9.00 | CRS and HIPEC for Peritoneal Mesothelioma : state of the art
<i>M. Deraco</i> |
|-----------|--|

Session 2: Now that we have proven the concept; how do we further improve it ?

- | | |
|-----------|--|
| 9.00-9.25 | What we can learn from Animal Models?
I. de Hingh |
|-----------|--|

9.25-9.50 What we can learn from the Pharmacologic Research?
W. Ceelen

09.50 - 10.15 Coffee break

Session 3: The Future of PSM Treatment

10.15-10.35 The 10 ongoing clinical trials that will change PSM Treatment
S. González-Moreno

10.35-11.00 How I foresee PSM treatment in 10 years' time
P. Sugarbaker

11.00-11.10 Final Remarks
K. Van der Speeten